---
title: Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma
date: '2024-09-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39265129/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240913200551&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Classic Hodgkin lymphoma (cHL) is highly curable at all stages. Research
  efforts over the past few decades have largely focused on interim PET-adapted strategies
  for therapy de-escalation or intensification. The overarching goals have been to
  increase cure rates, minimize potential therapy-related effects, and optimize survivorship.
  Better understanding of the biology of cHL has led to the development and approval
  of effective novel agents including the antibody-drug conjugate ...
disable_comments: true
---
Classic Hodgkin lymphoma (cHL) is highly curable at all stages. Research efforts over the past few decades have largely focused on interim PET-adapted strategies for therapy de-escalation or intensification. The overarching goals have been to increase cure rates, minimize potential therapy-related effects, and optimize survivorship. Better understanding of the biology of cHL has led to the development and approval of effective novel agents including the antibody-drug conjugate ...